Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EPS (Weighted Average and Diluted) (2021 - 2025)

Senti Biosciences has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.48 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.48 for Q4 2025, up 22.58% from a year ago — trailing twelve months through Dec 2025 was -$3.14 (up 73.9% YoY), and the annual figure for FY2025 was -$2.73, up 77.31%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.48 at Senti Biosciences, up from -$0.69 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for SNTI hit a ceiling of -$0.24 in Q4 2022 and a floor of -$8.24 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$2.45 (2024), compared with a mean of -$2.58.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 93.46% in 2022 and later tumbled 2396.97% in 2023.
  • Senti Biosciences' EPS (Weighted Average and Diluted) stood at -$3.67 in 2021, then skyrocketed by 93.46% to -$0.24 in 2022, then tumbled by 1641.67% to -$4.18 in 2023, then skyrocketed by 85.17% to -$0.62 in 2024, then increased by 22.58% to -$0.48 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.48 (Q4 2025), -$0.69 (Q3 2025), and -$0.56 (Q2 2025) per Business Quant data.